Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Mult Scler ; 22(6): 817-21, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26286699

RESUMEN

BACKGROUND: Mitoxantrone has been approved for patients with worsening relapsing-remitting (RR) or secondary progressive multiple sclerosis (SPMS), but its long-term use is limited by its cardiotoxicity. Pixantrone (PIX) is an analog of mitoxantrone. OBJECTIVES: The aim of this open-label, multicenter, noncomparative Phase I/II trial was to explore the immunosuppressive effect of PIX, its impact on clinical disease activity and cerebral gadolinium-enhanced (Gd(+)) lesions, and its safety. METHODS: Eighteen patients with active RRMS and SPMS (⩾ 1 cerebral Gd(+) lesion) despite approved immunomodulatory therapy received four intravenous PIX injections every 21 days. A neurological examination, hematology, lymphocyte subsets, and biochemistry were performed at Day 1, Weeks 3, 6 and 9, and Months 3, 6, 9 and 12. Echocardiography was performed before each infusion, at Months 3, 6 and 12. Cerebral MRI was performed at baseline, and at Months 6 and 12. RESULTS: CD19+ cells were reduced by 95% at Month 3 and by 47% at Month 12. Gd+ lesions were reduced by 86% at Month 12 (p = 0.01). The annual relapse rate was reduced by 87% (p < 10(-4)). Two patients experienced a transient reduction in left ventricular fraction. CONCLUSION: These preliminary data indicate the efficacy of PIX in active RRMS and SPMS.


Asunto(s)
Linfocitos B/efectos de los fármacos , Inmunosupresores/farmacología , Isoquinolinas/farmacología , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Evaluación de Resultado en la Atención de Salud , Inhibidores de Topoisomerasa II/farmacología , Adulto , Femenino , Humanos , Inmunosupresores/administración & dosificación , Isoquinolinas/administración & dosificación , Masculino , Persona de Mediana Edad , Inhibidores de Topoisomerasa II/administración & dosificación
2.
Brain ; 138(Pt 3): 632-43, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25616667

RESUMEN

Immunological hallmarks of multiple sclerosis include the production of antibodies in the central nervous system, expressed as presence of oligoclonal bands and/or an increased immunoglobulin G index-the level of immunoglobulin G in the cerebrospinal fluid compared to serum. However, the underlying differences between oligoclonal band-positive and -negative patients with multiple sclerosis and reasons for variability in immunoglobulin G index are not known. To identify genetic factors influencing the variation in the antibody levels in the cerebrospinal fluid in multiple sclerosis, we have performed a genome-wide association screen in patients collected from nine countries for two traits, presence or absence of oligoclonal bands (n = 3026) and immunoglobulin G index levels (n = 938), followed by a replication in 3891 additional patients. We replicate previously suggested association signals for oligoclonal band status in the major histocompatibility complex region for the rs9271640*A-rs6457617*G haplotype, correlated with HLA-DRB1*1501, and rs34083746*G, correlated with HLA-DQA1*0301 (P comparing two haplotypes = 8.88 × 10(-16)). Furthermore, we identify a novel association signal of rs9807334, near the ELAC1/SMAD4 genes, for oligoclonal band status (P = 8.45 × 10(-7)). The previously reported association of the immunoglobulin heavy chain locus with immunoglobulin G index reaches strong evidence for association in this data set (P = 3.79 × 10(-37)). We identify two novel associations in the major histocompatibility complex region with immunoglobulin G index: the rs9271640*A-rs6457617*G haplotype (P = 1.59 × 10(-22)), shared with oligoclonal band status, and an additional independent effect of rs6457617*G (P = 3.68 × 10(-6)). Variants identified in this study account for up to 2-fold differences in the odds of being oligoclonal band positive and 7.75% of the variation in immunoglobulin G index. Both traits are associated with clinical features of disease such as female gender, age at onset and severity. This is the largest study population so far investigated for the genetic influence on antibody levels in the cerebrospinal fluid in multiple sclerosis, including 6950 patients. We confirm that genetic factors underlie these antibody levels and identify both the major histocompatibility complex and immunoglobulin heavy chain region as major determinants.


Asunto(s)
Variación Genética , Inmunoglobulina G/líquido cefalorraquídeo , Complejo Mayor de Histocompatibilidad/genética , Esclerosis Múltiple/líquido cefalorraquídeo , Esclerosis Múltiple/genética , Polimorfismo de Nucleótido Simple/genética , Adolescente , Adulto , Anciano , Niño , Preescolar , Europa (Continente) , Femenino , Estudios de Asociación Genética , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/sangre , Bandas Oligoclonales/sangre , Bandas Oligoclonales/líquido cefalorraquídeo , Índice de Severidad de la Enfermedad , Proteína Smad4/genética , Proteínas Supresoras de Tumor/genética , Adulto Joven
3.
Mult Scler ; 21(12): 1533-45, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25662347

RESUMEN

BACKGROUND: Accumulating data highlight proinflammatory processes leading to MS relapses. Whether anti-inflammatory mechanisms are concomitantly activated is unclear. The ectonucleotidase CD39 has been described as a novel T regulatory cell (Treg) marker. The purpose of this study was to explore whether regulatory mechanisms are activated during MS relapses and reinforced by intravenous methylprednisolone (ivMP). METHODS: Blood samples were collected from stable and relapsing MS patients and healthy controls. We used FOXP3 methylation-specific qPCR and CD4(+)CD25(high)FOXP3(+) analysis to quantify Tregs. Cytokine mRNA expression levels were measured in peripheral blood mononuclear cells (PBMCs) and in CD4(+) T cells. CD39 expression was determined by flow cytometry in monocytes, NK, T and B cells. CD39 enzymatic activity was assessed by ATP luminometry. RESULTS: The proportion of Tregs was similar in relapsing MS patients and healthy controls. CD39 mRNA level was higher in PBMCs of relapsing MS patients than in controls. The proportion of CD39-expressing Tregs was higher in MS patients. IvMP decreased the overall proportion of Tregs while it increased CD39 mRNA levels, the proportions of CD39-expressing Tregs and monocytes as well as CD39 ectonucleotidase activity. CONCLUSIONS: Our data suggest that immunoregulatory mechanisms are ongoing in MS patients, particularly during relapses, and strengthened by ivMP.


Asunto(s)
Antígenos CD/metabolismo , Apirasa/metabolismo , Glucocorticoides/farmacología , Metilprednisolona/farmacología , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Linfocitos T Reguladores/metabolismo , Administración Intravenosa , Adulto , Antígenos CD/efectos de los fármacos , Apirasa/efectos de los fármacos , Glucocorticoides/administración & dosificación , Humanos , Metilprednisolona/administración & dosificación , Esclerosis Múltiple Recurrente-Remitente/sangre , Linfocitos T Reguladores/efectos de los fármacos , Resultado del Tratamiento
4.
Curr Opin Neurol ; 26(5): 510-5, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23945279

RESUMEN

PURPOSE OF REVIEW: Infectious neuropathies are heterogeneous neuropathies with multiple causes. They still represent an important world health burden and some of them have no current available therapy. RECENT FINDINGS: Leprosy incidence has decreased by 50% during the last years, but leprosy-related neuropathies still cause severe disability. The pure neuritic leprosy is a diagnostic challenge that may require nerve biopsy or nerve aspiration cytology. The treatment itself may lead to a 'reversal reaction', which further causes injuries to the nerve. HCV-related neuropathies may be related or not to the presence of cryoglobulins. The absence of vasculitis, the most frequent form is a peripheral sensory neuropathy involving small nerve fibers, and more accurately diagnosed by pain-related evoked potentials. HIV-related neuropathy has become the major neurological complication of HIV infection. Both HIV-induced neuropathy and antiretroviral toxic neuropathy are clinically indistinguishable. The existence of an isolated chronic polyneuropathy due to Borrelia burgdorferi remains highly controversial. Lastly, an active infectious ganglioneuritis caused by varicella zoster virus, producing shingles, is the most frequent infectious neuropathy in the world and may cause various neurological complications. Zoster sine herpete remains frequently undiagnosed. SUMMARY: Recent data have improved our knowledge and diagnostic tools of infectious neuropathies. Treatment of the injured nerves is not yet available, and prevention and rapid diagnosis remain the main priorities for the clinician.


Asunto(s)
Infecciones/complicaciones , Enfermedades del Sistema Nervioso Periférico/diagnóstico , Enfermedades del Sistema Nervioso Periférico/etiología , Biopsia/métodos , Diagnóstico Precoz , Humanos , Infecciones/diagnóstico , Inflamación/complicaciones , Lepra/complicaciones , Lepra/diagnóstico , Lepra/terapia , Enfermedades del Sistema Nervioso Periférico/prevención & control , Enfermedades del Sistema Nervioso Periférico/terapia
5.
Neurocrit Care ; 18(1): 89-92, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23090840

RESUMEN

BACKGROUND: To describe a case of auto-immune encephalitis in an adolescent with favorable outcome despite prolonged status epilepticus. METHODS: A 17 year old Asian man without previous medical history developed alteration of consciousness and partial seizures. The diagnosis of anti-N-methyl-D-aspartate receptor encephalitis was confirmed by the detection of specific antibodies in both cerebrospinal fluid and serum. RESULTS: The clinical course was complicated by prolonged status epilepticus which was refractory to a large number of antiepileptic drugs, including barbiturate coma. Immunomodulatory therapy included steroids, plasma exchanges, and intravenous immunoglobulins. After 86 days of intensive therapy, the patient regained consciousness progressively. Brain magnetic resonance imaging never demonstrated any lesion. Extensive search for a tumor was negative. At 12 month follow-up, the patient had made an excellent recovery. CONCLUSION: Auto-immune encephalitis is likely underdiagnosed in adolescents. In their most severe presentation, seizures may be resistant to a large number of anti-epileptic drugs, and the clinical improvement seems to be mainly because of the immunomodulatory therapy. Relapse is possible, as well as the delayed development of a teratoma or other tumor.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/tratamiento farmacológico , Anticonvulsivantes/uso terapéutico , Inmunosupresores/uso terapéutico , Estado Epiléptico/tratamiento farmacológico , Adolescente , Encefalitis Antirreceptor N-Metil-D-Aspartato/complicaciones , Humanos , Masculino , Estado Epiléptico/etiología , Resultado del Tratamiento
6.
J Neurochem ; 123(4): 568-77, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22958230

RESUMEN

Limited information is available on the identity of antigens targeted by antibodies present in cerebrospinal fluid (CSF) of patients with clinically isolated syndrome (CIS). The aim of this study was to identify novel antigens for CIS and investigate their prognostic potential to predict conversion to multiple sclerosis (MS). We applied serological antigen selection (SAS) to identify antigens interacting with antibodies present in the pooled CSF from four CIS patients, who developed MS. Antibody reactivity towards CIS antigens identified by SAS was tested in CSF and serum from patients with CIS (n = 123/n = 108), MS (n = 65/n = 44), and other (inflammatory) neurological diseases (n = 75/n = 38) as well as in healthy control sera (n = 44). Using SAS, a panel of six novel CIS candidate antigens was identified. CSF antibody reactivity was detected in both CIS and relapsing-remitting (RR) MS. Serum reactivity was significantly increased in CIS and RR-MS as compared with controls (p = 0.03). For two antigens, the frequency of antibody-positive patients was higher in CIS patients who converted to MS as compared with CIS patients without conversion. We identified novel CIS antigens to which antibody reactivity was primarily detected in CIS and RR-MS as compared to controls. Possible prognostic potential could be demonstrated for two antigens.


Asunto(s)
Antígenos/inmunología , Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Enfermedades Desmielinizantes/sangre , Enfermedades Desmielinizantes/líquido cefalorraquídeo , Adolescente , Adulto , Reacciones Antígeno-Anticuerpo , Evaluación de la Discapacidad , Ensayo de Inmunoadsorción Enzimática , Femenino , Factor C1 de la Célula Huésped/inmunología , Humanos , Masculino , Esclerosis Múltiple/sangre , Esclerosis Múltiple/líquido cefalorraquídeo , Proteínas de la Mielina/inmunología , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/aislamiento & purificación , Valor Predictivo de las Pruebas , Pruebas Serológicas
7.
BMC Neurol ; 11: 68, 2011 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-21649910

RESUMEN

BACKGROUND: There is need for a cognitive test battery that can be easily used in clinical practice to detect or monitor cognitive performance in patients with multiple sclerosis (MS). In order to conduct, in this patient group, a preliminary investigation of the validity and utility of a brief computerized battery, the Cognitive Drug Research (CDR) battery, we longitudinally assessed cognition in patients with relapsing remitting (RR) MS. METHODS: Forty-three mildly disabled, clinically active RRMS patients were repeatedly assessed with the Digit Symbol Substitution Test (DSST), Paced Auditory Serial Addition Test (PASAT) and five composite scores derived from the CDR computerized cognitive test system (CDR System): Power of Attention, Continuity of Attention, Quality of Working Memory, Quality of Episodic Memory and Speed of Memory. The Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) measured disability. RESULTS: The composite scores from the CDR battery generally showed excellent test-retest reliability over the repeated assessments, though was low on occasions for the Quality of Working Memory and Quality of Episodic Memory measures. The CDR measures tended to be highly correlated with other measures of cognition (DSST and PASAT) and were also strongly related to disability (EDSS and MSFC). Baseline scores indicated large impairments to visual information processing speed and attention (DSST, Cohen's d 1.1; Power of Attention d 1.4 [reaction time on tasks of focussed and sustained attention]), and a moderate impairment both to sustained attention (Continuity of Attention d 0.6) and complex information processing speed (Speed of memory d 0.7 [reaction time on tasks of working and episodic Memory]), when compared to normative data derived from healthy volunteers enrolled in a series of separate, prior clinical trials. Working memory (Quality of Working Memory) and episodic memory (Quality of Episodic Memory) were unimpaired. CONCLUSIONS: Preliminary validation of the CDR System indicated that for most, but not all measures psychometric properties were adequate and the measures were related to disability (EDSS and MSFC) and other measures of cognition.


Asunto(s)
Trastornos del Conocimiento/diagnóstico , Trastornos del Conocimiento/etiología , Diagnóstico por Computador/métodos , Esclerosis Múltiple Recurrente-Remitente/complicaciones , Pruebas Neuropsicológicas , Estimulación Acústica , Adolescente , Adulto , Anciano , Evaluación de la Discapacidad , Femenino , Humanos , Estudios Longitudinales , Masculino , Memoria/fisiología , Persona de Mediana Edad , Calidad de Vida , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad , Estadística como Asunto , Factores de Tiempo , Adulto Joven
8.
J Neurosci ; 29(15): 4708-18, 2009 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-19369541

RESUMEN

Synchronous calcium oscillations are observed in primary cultures of rat cortical neurons when mature networks are formed. This spontaneous neuronal activity needs an accurate control of calcium homeostasis. Alteration of intraneuronal calcium concentration is described in many neurodegenerative disorders, including Alzheimer disease (AD). Although processing of amyloid precursor protein (APP) that generates Abeta peptide has critical implications for AD pathogenesis, the neuronal function of APP remains unclear. Here, we report that expression of human APP (hAPP) in rat cortical neurons increases L-type calcium currents, which stimulate SK channels, calcium-dependent K(+) channels responsible for medium afterhyperpolarization (mAHP). In a neuronal network, increased mAHP in some neurons expressing hAPP leads to inhibition of calcium oscillations in all the cells of the network. This inhibition is independent of production and secretion of Abeta and other APP metabolites. In a neuronal network, reduction of endogenous APP expression using shRNA increases the frequency and reduces the amplitude of calcium oscillations. Altogether, these data support a key role for APP in the control of neuronal excitability.


Asunto(s)
Precursor de Proteína beta-Amiloide/biosíntesis , Señalización del Calcio/fisiología , Calcio/antagonistas & inhibidores , Corteza Cerebral/fisiología , Regulación hacia Abajo/fisiología , Neuronas/fisiología , Precursor de Proteína beta-Amiloide/antagonistas & inhibidores , Precursor de Proteína beta-Amiloide/genética , Animales , Calcio/metabolismo , Canales de Calcio Tipo L/biosíntesis , Canales de Calcio Tipo L/genética , Canales de Calcio Tipo L/metabolismo , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/metabolismo , Humanos , Neuronas/citología , Neuronas/metabolismo , ARN Interferente Pequeño/genética , Ratas , Ratas Wistar
10.
Mult Scler ; 16(4): 455-62, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20200198

RESUMEN

Anti-inflammatory drugs are effective on relapses, but neuroprotective agents to prevent disability are still unavailable. Uric acid has neuroprotective effects in experimental models including encephalomyelitis and appears to be involved in multiple sclerosis. Oral administration of inosine, a precursor of uric acid, increases serum uric acid levels and is well tolerated. Our objective was to test the possibility that a combination therapy associating an anti-inflammatory drug (interferon beta) and an endogenous neuroprotective molecule (uric acid) would be more effective than interferon beta alone on the accumulation of disability. Patients with relapsing-remitting multiple sclerosis on interferon beta for at least 6 months were randomized to interferon beta + inosine or interferon beta + placebo for 2 years. The dose of inosine was adjusted to maintain serum uric acid levels in the range of asymptomatic hyperuricaemia (

Asunto(s)
Antiinflamatorios/uso terapéutico , Inosina/uso terapéutico , Interferón beta/uso terapéutico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Fármacos Neuroprotectores/uso terapéutico , Adulto , Antiinflamatorios/efectos adversos , Bélgica , Evaluación de la Discapacidad , Progresión de la Enfermedad , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Inosina/efectos adversos , Inosina/metabolismo , Interferón beta-1a , Interferon beta-1b , Interferón beta/efectos adversos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Esclerosis Múltiple Recurrente-Remitente/sangre , Esclerosis Múltiple Recurrente-Remitente/diagnóstico , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/metabolismo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Ácido Úrico/sangre
11.
Neurosci Lett ; 414(3): 257-62, 2007 Mar 13.
Artículo en Inglés | MEDLINE | ID: mdl-17223267

RESUMEN

Long-term potentiation (LTP) is a persistent increase in the strength of synaptic transmission triggered by neuronal activity. Here, we submitted hippocampal slices to a perfusion of forskolin and IBMX, which induces a long-lasting LTP (>4 h) (L-LTP). We separated the proteins of the CA1 region by two-dimensional gel electrophoresis (2-DE). We then immunoblotted them using an anti-p-Tyr antibody. We found a protein whose tyrosine phosphorylation was unchanged 10 min after LTP induction but was dramatically increased after 1h, dropping back to its baseline after 4 h. This protein was identified as rabphilin using matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS). We also demonstrated that genistein, an inhibitor of tyrosine phosphorylation, prevented the development of the late phase of electrically-induced L-LTP. Our results suggest that rabphilin, a protein present in presynaptic terminals, could play a role in the late phase of L-LTP.


Asunto(s)
Hipocampo/metabolismo , Potenciación a Largo Plazo/fisiología , Proteínas del Tejido Nervioso/metabolismo , Vías Nerviosas/metabolismo , Terminales Presinápticos/metabolismo , 1-Metil-3-Isobutilxantina/farmacología , Animales , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Colforsina/farmacología , Inhibidores Enzimáticos/farmacología , Genisteína/farmacología , Hipocampo/efectos de los fármacos , Potenciación a Largo Plazo/efectos de los fármacos , Masculino , Espectrometría de Masas , Ratones , Ratones Endogámicos C57BL , Proteínas del Tejido Nervioso/análisis , Proteínas del Tejido Nervioso/química , Vías Nerviosas/efectos de los fármacos , Técnicas de Cultivo de Órganos , Inhibidores de Fosfodiesterasa/farmacología , Fosforilación/efectos de los fármacos , Terminales Presinápticos/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Tirosina/metabolismo
13.
PLoS One ; 12(3): e0173780, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28301515

RESUMEN

Multiple sclerosis (MS) is thought to be a Th17-mediated dysimmune disease of the central nervous system. However, recent publications have questioned the pathogenicity of IL-17 per se and rather suggest the implication of other Th17-related inflammatory mediators. Therefore, we studied the expression of GM-CSF, IL-22, IL-24, IL-26 and CD39 in peripheral blood mononuclear cells (PBMCs) from MS patients during relapses, remission and following corticosteroid treatment. We performed qPCR to measure mRNA levels from ex vivo or in vitro-stimulated PBMCs. Cytokine levels were determined by ELISA. We used flow cytometry to assess GM-CSF+, IL-22+ and CD39+ cells in relationship to IL-17+ CD4+ T cells. Our results showed that IL-22 mRNA and IL-22+CD4+ lymphocytes are increased in circulating cells of relapsing MS patients compared to remitting patients while GM-CSF was unchanged. We have further shown that 12.9, 39 and 12.4% of Th17 cells from MS patients during relapses expressed IL-22, GM-CSF and CD39 respectively. No changes in these proportions were found in stable MS patients. However, the majority of GM-CSF+ or IL-22+ T cells did not co-express IL-17. GM-CSF mRNA, but not IL-22 mRNA, was dramatically decreased ex vivo by ivMP. Our results contribute to a better characterisation of Th17, Th22 and ThGM-CSF cells in the setting of MS and according to disease activity.


Asunto(s)
Corticoesteroides/uso terapéutico , Factor Estimulante de Colonias de Granulocitos y Macrófagos/sangre , Interleucina-17/sangre , Interleucinas/sangre , Esclerosis Múltiple/sangre , Esclerosis Múltiple/tratamiento farmacológico , Adolescente , Adulto , Estudios de Casos y Controles , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/patología , ARN Mensajero/sangre , Adulto Joven , Interleucina-22
14.
Clin Neurol Neurosurg ; 149: 55-63, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27475049

RESUMEN

Clinical trials have shown that natalizumab is highly effective for treating relapsing forms of multiple sclerosis (MS). The purpose of this analysis was to conduct a targeted review of data from country-specific observational studies and registries of natalizumab-treated patients with relapsing MS in order to more fully investigate the longer-term effectiveness and safety of this disease-modifying therapy in real-world clinical practice settings. A PubMed search was conducted on March 13, 2014, using the terms (natalizumab AND multiple sclerosis) AND (observational OR registry OR post-marketing OR clinical practice). Only English-language papers that reported effectiveness (in terms of effects on relapses, disability progression, and magnetic resonance imaging findings) and/or safety results from studies were included. Data from 22 studies/registries were included. Annualized relapse rates decreased by 73%-94% from baseline across the studies, with improvement maintained for up to 5 years during natalizumab treatment. Natalizumab effectiveness was also demonstrated via assessment of disability progression (Expanded Disability Status Scale), radiological measures, and no-evidence-of-disease-activity measures (clinical, radiological, and overall). Results were similar among patient groups stratified by level of disease activity. Safety outcomes were consistent with natalizumab's known safety profile. Data from country-specific observational studies and registries varying in size and scope support the effectiveness and safety of natalizumab in a broad range of patients in clinical practice.


Asunto(s)
Factores Inmunológicos/farmacología , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Natalizumab/farmacología , Estudios Observacionales como Asunto/estadística & datos numéricos , Evaluación de Resultado en la Atención de Salud/estadística & datos numéricos , Humanos , Factores Inmunológicos/efectos adversos , Natalizumab/efectos adversos
15.
J Alzheimers Dis ; 49(2): 271-6, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26444777

RESUMEN

We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.


Asunto(s)
Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/complicaciones , Biomarcadores/líquido cefalorraquídeo , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/etiología , Tetrahidronaftalenos/uso terapéutico , Anciano , Enfermedad de Alzheimer/tratamiento farmacológico , Proteínas Amiloidogénicas/líquido cefalorraquídeo , Bexaroteno , Humanos , Masculino , Recuerdo Mental/efectos de los fármacos , Recuerdo Mental/ética , Pruebas Neuropsicológicas , Receptores de Ácido Retinoico/agonistas , Proteínas tau/líquido cefalorraquídeo
16.
Arch Neurol ; 62(6): 865-70, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15956157

RESUMEN

New criteria for the diagnosis of multiple sclerosis (MS) were published as the result of an internationally formed committee. To increase the specificity of diagnosis and to minimize the number of false diagnoses, the committee recommended the use of both clinical and paraclinical criteria, the latter involving information obtained from magnetic resonance imaging, evoked potentials, and cerebrospinal fluid (CSF) analysis. Although rigorous magnetic resonance imaging requirements were provided, the "new criteria paper" fell short in terms of guidelines as to how the CSF analysis should be performed and simply equated the IgG index with isoelectric focusing, without any justification. The spectrum of parameters analyzed and methods for CSF analysis differ worldwide and often yield variable results in terms of sensitivity, specificity, accuracy, and reliability, with no decided "optimal" CSF test for the diagnosis of MS. To address this question specifically, an international panel of experts in MS and CSF diagnostic techniques was convened and the result was this article, representing a consensus of all the participants. These recommendations for establishing a standard for the evaluation of CSF in patients suspected of having MS should greatly complement the new criteria in ensuring that a correct diagnosis of MS is being made.


Asunto(s)
Esclerosis Múltiple/líquido cefalorraquídeo , Esclerosis Múltiple/diagnóstico , Conferencias de Consenso como Asunto , Humanos , Inmunoglobulina G/líquido cefalorraquídeo
17.
J Neurol ; 252(10): 1217-22, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15834643

RESUMEN

Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS). From a cohort of 820 MS patients, 52 (6%) were treated with this drug between December 1991 and April 2003. Mitoxantrone was administered at a dose of 12 mg/m(2) once a month for three months and then at three-month intervals to reach a total cumulative dose of 144 mg/m(2). The left ventricular ejection fraction was checked by radionuclide ventriculography prior to treatment and every six months. Treatment was stopped if the ejection fraction was below 50% in two consecutive ventriculographies performed one to three months apart. Cardiotoxicity during the course of the treatment was not observed. However, three patients developed congestive heart failure 24, 39 and 80 months after the last dose of mitoxantrone. Other cardiac causes were excluded. Two of these patients had been treated previously with cyclophosphamide. All patients first recovered on medical treatment, but two worsened a few months later. One patient remained severely symptomatic in spite of optimal medical treatment. Although mitoxantrone is generally well tolerated and reduces progression of disability and clinical exacerbations, our observation of a delayed cardiotoxicity makes necessary a long-term follow-up of MS patients treated with this drug.


Asunto(s)
Insuficiencia Cardíaca/inducido químicamente , Mitoxantrona/toxicidad , Esclerosis Múltiple Crónica Progresiva/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Esclerosis Múltiple/tratamiento farmacológico , Adulto , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/patología , Humanos , Masculino , Persona de Mediana Edad , Mitoxantrona/uso terapéutico , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
18.
AJNR Am J Neuroradiol ; 26(3): 496-501, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15760855

RESUMEN

We report the serial MR imaging and neuropathologic findings in a patient with fibrocartilaginous embolism to the spinal cord, presumptively originating from vertebral body endplates. Extensive increased T2 signal intensity, minimal contrast enhancing foci, concomitant vertebral body bone marrow infarction, and terminal cord hemorrhagic necrosis were the main MR imaging features. Pathologic examination of the cord demonstrated arteriolar occlusions by chondrocytic thrombi resulting in hemorrhagic necrosis.


Asunto(s)
Cartílago/patología , Embolia/diagnóstico , Imagen por Resonancia Magnética , Médula Espinal/irrigación sanguínea , Médula Espinal/patología , Anciano , Médula Ósea/irrigación sanguínea , Embolia/patología , Resultado Fatal , Femenino , Hemorragia/etiología , Hemorragia/patología , Humanos , Infarto/etiología , Necrosis , Vértebras Torácicas/irrigación sanguínea
19.
PLoS One ; 10(12): e0145497, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26693908

RESUMEN

Brain blood barrier breakdown as assessed by contrast-enhanced (CE) T1-weighted MR imaging is currently the standard radiological marker of inflammatory activity in multiple sclerosis (MS) patients. Our objective was to evaluate the performance of an alternative model assessing the inflammatory activity of MS lesions by texture analysis of T2-weighted MR images. Twenty-one patients with definite MS were examined on the same 3.0T MR system by T2-weighted, FLAIR, diffusion-weighted and CE-T1 sequences. Lesions and mirrored contralateral areas within the normal appearing white matter (NAWM) were characterized by texture parameters computed from the gray level co-occurrence and run length matrices, and by the apparent diffusion coefficient (ADC). Statistical differences between MS lesions and NAWM were analyzed. ROC analysis and leave-one-out cross-validation were performed to evaluate the performance of individual parameters, and multi-parametric models using linear discriminant analysis (LDA), partial least squares (PLS) and logistic regression (LR) in the identification of CE lesions. ADC and all but one texture parameter were significantly different within white matter lesions compared to within NAWM (p < 0.0167). Using LDA, an 8-texture parameter model identified CE lesions with a sensitivity Se = 70% and a specificity Sp = 76%. Using LR, a 10-texture parameter model performed better with Se = 86% / Sp = 84%. Using PLS, a 6-texture parameter model achieved the highest accuracy with Se = 88% / Sp = 81%. Texture parameter from T2-weighted images can assess brain inflammatory activity with sufficient accuracy to be considered as a potential alternative to enhancement on CE T1-weighted images.


Asunto(s)
Encéfalo/diagnóstico por imagen , Inflamación/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Esclerosis Múltiple/patología , Barrera Hematoencefálica , Encéfalo/patología , Humanos , Inflamación/patología , Esclerosis Múltiple/diagnóstico por imagen , Reconocimiento de Normas Patrones Automatizadas , Curva ROC , Intensificación de Imagen Radiográfica/métodos
20.
Neuroreport ; 14(12): 1585-9, 2003 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-14502081

RESUMEN

In the vestibular nuclei of the awake guinea pig, all neurones are spontaneously active. After unilateral labyrinthectomy, this activity virtually disappears on the ipsilateral side, but is completely restored one week later. In a recent study, we observed that the restoration of spontaneous activity was correlated with an increase in pacemaker activity. In the current study, we found that the ratio of medial vestibular nucleus (MVN) neurones endowed with one of the currents known to play a role in pacemaker activity (i.e. low-threshold calcium current; LTCC) increased from 29% in control guinea pigs to 65% in animals labyrinthectomised on the ipsilateral side one week earlier. Yet this change was not correlated with a modification of the ratio of neurones expressing any of the three related protein-channels (alpha1G, alpha1H and alpha1I).


Asunto(s)
Potenciales de Acción/fisiología , Canales de Calcio Tipo T/biosíntesis , Oído Interno/fisiología , Oído Interno/cirugía , Nervio Vestibular/fisiología , Animales , Canales de Calcio Tipo T/metabolismo , Canales de Calcio Tipo T/fisiología , Femenino , Cobayas , Técnicas In Vitro
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA